#43
Long-Term Treatment with Vardenafil Reduces the Development of the Fibrotic Plaque in a Rat Model of Peyronie's Disease
Ferrini, M; Kovanecz, T; Nolazco, G; Rajfer, J; Gonzalez-Cadavid, N (presented by: Monica Ferrini, PhD)
Introduction and Objectives: We have previously demonstrated that long-term (45 days) continuous administration of high doses (l0mg/kg/day) of a PDE5 inhibitor, sildenafil, prevents the development of the PD-like plaque in the rat model of Pyeronie's disease (PD), through the increase of cGMP levels in the target tissues, which presumably acts as an anti fibrotic agent. In the current work we have determined whether vardenafil given orally at lower doses and different regimes, achieves a similar effect.
|
UroToday, 1802 Fifth Street, Berkeley CA 94710 510.540.0930 (fax), info@urotoday.com ISSN 1939-4810 UroToday International Journal Correspondence
Privacy Policy | © 2010 UroToday ® All Rights Reserved |
